NASDAQ:GNMK - GenMark Diagnostics Stock Price, Forecast & News

GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."

GenMark Diagnostics, Inc (NASDAQ:GNMK) posted its quarterly earnings data on Wednesday, November, 6th. The medical equipment provider reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.01. The medical equipment provider had revenue of $20.92 million for the quarter, compared to analyst estimates of $20.66 million. GenMark Diagnostics had a negative return on equity of 239.16% and a negative net margin of 60.63%. View GenMark Diagnostics' Earnings History.

GenMark Diagnostics is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for GenMark Diagnostics.

GenMark Diagnostics will be holding an earnings conference call on Monday, March 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

GenMark Diagnostics issued an update on its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $88-88 million, compared to the consensus revenue estimate of $88.3 million.

3 brokers have issued 1 year price objectives for GenMark Diagnostics' shares. Their forecasts range from $7.00 to $9.00. On average, they anticipate GenMark Diagnostics' stock price to reach $8.00 in the next year. This suggests a possible upside of 96.1% from the stock's current price. View Analyst Price Targets for GenMark Diagnostics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GenMark Diagnostics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GenMark Diagnostics.

Media coverage about GNMK stock has trended very negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GenMark Diagnostics earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for GenMark Diagnostics.

GenMark Diagnostics saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 1,770,000 shares, a decrease of 5.9% from the January 15th total of 1,880,000 shares. Based on an average daily volume of 294,300 shares, the days-to-cover ratio is presently 6.0 days. Currently, 3.3% of the shares of the company are sold short. View GenMark Diagnostics' Current Options Chain.

Some companies that are related to GenMark Diagnostics include Intersect ENT (XENT), Orthofix Medical (OFIX), Cerus (CERS), MiMedx Group (MDXG), Orthopediatrics (KIDS), LeMaitre Vascular (LMAT), Anika Therapeutics (ANIK), Antares Pharma (ATRS), SurModics (SRDX), SI-Bone (SIBN), AngioDynamics (ANGO), Alphatec (ATEC), OraSure Technologies (OSUR), Inovio Pharmaceuticals (INO) and Utah Medical Products (UTMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other GenMark Diagnostics investors own include Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), T2 Biosystems (TTOO), NovaBay Pharmaceuticals (NBY), Biocept (BIOC), Amicus Therapeutics (FOLD), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), VBI Vaccines (VBIV) and Catalyst Pharmaceuticals (CPRX).

GenMark Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.99%), Cadian Capital Management LP (9.50%), Bank of America Corp DE (3.61%), State Street Corp (1.89%), Penn Capital Management Co. Inc. (1.68%) and Geode Capital Management LLC (1.31%). Company insiders that own GenMark Diagnostics stock include Brian Andrew Mitchell, Eric Stier, Hany Massarany, James B Mcnally, Jennifer Anne Williams, John Frederick Ek, Kevin C Oboyle, Michael Gleeson, Michael Kagnoff, Sarah Hollis Winkler, Scott Mendel and Tyler Jensen. View Institutional Ownership Trends for GenMark Diagnostics.

GNMK stock was sold by a variety of institutional investors in the last quarter, including Cadian Capital Management LP, AQR Capital Management LLC, Oxford Asset Management LLP, Goldman Sachs Group Inc., Panagora Asset Management Inc., TD Asset Management Inc., Blair William & Co. IL and Man Group plc. Company insiders that have sold GenMark Diagnostics company stock in the last year include Brian Andrew Mitchell, Eric Stier, Hany Massarany, James B Mcnally, John Frederick Ek, Kevin C Oboyle, Michael Gleeson, Sarah Hollis Winkler, Scott Mendel and Tyler Jensen. View Insider Buying and Selling for GenMark Diagnostics.

GNMK stock was purchased by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Parkman Healthcare Partners LLC, Point72 Asset Management L.P., Penn Capital Management Co. Inc., Granite Investment Partners LLC, Jacobs Levy Equity Management Inc., Renaissance Technologies LLC and FMR LLC. View Insider Buying and Selling for GenMark Diagnostics.

Shares of GNMK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GNMK stock can currently be purchased for approximately $4.08.

GenMark Diagnostics has a market capitalization of $236.97 million and generates $70.76 million in revenue each year. The medical equipment provider earns $-50,500,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. GenMark Diagnostics employs 477 workers across the globe.View Additional Information About GenMark Diagnostics.

The official website for GenMark Diagnostics is http://www.genmarkdx.com/.

GenMark Diagnostics' mailing address is 5964 LA PLACE COURT, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-448-4300 or via email at [email protected]